All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @movability on TikTok · 53s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @movability's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00If you lost your sense of smell after being sick, listen up, it's not in your head.
  2. 0:03Here's the science in 10 seconds. Viruses inflame the smell zone in your nose and not
  3. 0:08cut the support cells your neurons need. The neurons go quiet even without congestion.
  4. 0:12They can regenerate but slowly.
  5. 0:14Timeline. Week 1 to 4, many get wiffs back. Week 4 to 12, it can be patchy and
  6. 0:19pyrozmia which is when things smell wrong often shows up during this rewiring process.
  7. 0:24Beyond three months, it can still come back but get checked if it's one-sided or worsening.
  8. 0:29At home, smell training twice daily, rose, lemon, clove, eucalyptus, 20 seconds each for 12 weeks.
  9. 0:37Use saline rinses, manage allergies, prioritize sleep, protein and omega-3s, never use zinc nasal
  10. 0:42sprays. Save this and share it with someone who lost their sense of smell. For the full deep dive
  11. 0:47and exact protocol, visit movability masterclass on Southstack. Link is up there. More details in
  12. 0:51the caption below.

@movability's anosmia claims need context, not hype

Movability

TikTok creator

16.4K viewsWatch on TikTok

Quick answer

Post-viral olfactory dysfunction affects an estimated 5-10% of COVID-19 patients beyond 12 weeks, based on meta-analyses published through 2023. The primary mechanism involves sustentacular cell injury rather than direct olfactory neuron damage, though persistent cases may involve olfactory bulb inflammation or central processing changes. Olfactory training has level 1b evidence for post-viral cases, but patients with worsening, unilateral, or neurologically complex presentations require formal ENT or neurology evaluation rather than home protocols alone.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @movability's anosmia claims need context, not hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@movability's anosmia claims need context, not hype should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@movability's anosmia claims need context, not hype" from Movability. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Post-viral olfactory dysfunction affects an estimated 5-10% of COVID-19 patients beyond 12 weeks, based on meta-analyses published through 2023.

The reason this review is not generic is the source wording and the canonical claim label "trt lost your sense of smell after being sick this is called po." In this clip, the useful excerpt is: "If you lost your sense of smell after being sick, listen up, it's not in your head." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

A 2022 Laryngoscope systematic review found median smell recovery after COVID-19 at roughly 30 days, but a meaningful subset takes 3 or more months, and some cases persist beyond a year.
People who land here are usually trying to understand whether the Testosterone claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Post-viral olfactory dysfunction affects an estimated 5-10% of COVID-19 patients beyond 12 weeks, based on meta-analyses published through 2023.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Post-viral olfactory dysfunction affects an estimated 5-10% of COVID-19 patients beyond 12 weeks, based on meta-analyses published through 2023. The primary mechanism involves sustentacular cell injury rather than direct olfactory neuron damage, though persistent cases may involve olfactory bulb inflammation or central processing changes. Olfactory training has level 1b evidence for post-viral cases, but patients with worsening, unilateral, or neurologically complex presentations require formal ENT or neurology evaluation rather than home protocols alone.
  • Brann et al. (2020, Chemical Senses) confirmed sustentacular support cells, not olfactory neurons directly, are the primary COVID-19 target in the olfactory epithelium, explaining smell loss without nasal congestion.
  • A 2022 Laryngoscope systematic review found median smell recovery after COVID-19 at roughly 30 days, but a meaningful subset takes 3 or more months, and some cases persist beyond a year.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Brann et al. (2020, Chemical Senses) confirmed sustentacular support cells, not olfactory neurons directly, are the primary COVID-19 target in the olfactory epithelium, explaining smell loss without nasal congestion.
  • A 2022 Laryngoscope systematic review found median smell recovery after COVID-19 at roughly 30 days, but a meaningful subset takes 3 or more months, and some cases persist beyond a year.
  • The 4-scent olfactory training protocol in this video matches the Hummel et al. (2009) RCT design, which is the most-cited evidence base for this intervention and has been replicated in post-COVID cohorts.
  • The FDA issued a 2009 safety warning on intranasal zinc products after reports of permanent smell loss; the creator's warning to avoid zinc nasal sprays is clinically valid.
  • Parosmia, where familiar smells are distorted or smell unpleasant, is a recognized phase of olfactory recovery and often signals active neural rewiring rather than worsening, according to long-COVID clinic data.
  • Unilateral anosmia, smell loss with no preceding illness, or anosmia accompanied by headache or neurological symptoms requires imaging and specialist evaluation, not home smell training.
  • Pellegrino et al. (2021, JAMA Otolaryngology) suggested higher-intensity odorants may improve training outcomes over the classic rose-lemon-clove-eucalyptus set, though any consistent high-quality odorant exposure likely confers benefit.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @movability actually say?

The creator laid out a rapid-fire explainer on post-viral olfactory dysfunction, covering the biology, a recovery timeline, and a home protocol. They claimed viruses damage "support cells" the olfactory neurons depend on, described a 1-to-12-week recovery window, named parosmia as a sign of "rewiring," and recommended smell training with rose, lemon, clove, and eucalyptus twice daily for 12 weeks. They also said to "never use zinc nasal sprays." The framing is confident and clinical, which raises the question of whether the confidence is earned.

Does the science back this up?

Mostly, yes, with some important nuances. The support cell story is real. COVID-19 and other respiratory viruses preferentially infect sustentacular cells, which are the non-neuronal support cells in the olfactory epithelium, rather than the neurons themselves. This is well-documented. Brann et al. (2020, Chemical Senses) and subsequent work confirmed ACE2 expression is higher in sustentacular cells than in olfactory sensory neurons, which explains why many patients lose smell without full nasal blockage. The timeline the creator gives is broadly consistent with observational data. A 2022 systematic review by Tan et al. in the Laryngoscope found median smell recovery after COVID at around 30 days, with a subset taking 3-plus months. Parosmia appearing during recovery is also well-documented, and the smell training recommendation has actual RCT support behind it. The zinc nasal spray warning is also correct and important.

What did they get wrong or right?

The creator mispronounced and slightly fumbled the term "parosmia," calling it "pyrozmia," which is a minor issue in video but could confuse viewers searching for more information. More substantively, they said viruses "not cut" support cells, which appears to be a garbled transcript of "do cut off" or damage, suggesting the verbal delivery was unclear in the original video. The support cell mechanism is accurate, but calling neuronal recovery "regeneration" oversimplifies it. Olfactory sensory neurons do have regenerative capacity, unlike most CNS neurons, but the process involves basal stem cell repopulation, and in some long-COVID cases there is evidence of persistent epithelial disruption. The creator deserves credit for the zinc nasal spray warning. Intranasal zinc, particularly zinc gluconate products like Zicam, has been linked to permanent anosmia in case reports and a 2009 FDA advisory. That is a genuinely useful safety point that many influencers skip.

What should you actually know?

Post-viral olfactory dysfunction is real, common, and usually temporary but not always. The smell training protocol the creator recommends, four odorants twice daily for at least 12 weeks, is supported by randomized controlled trial data. Hummel et al. (2009, The Laryngoscope) first established this approach, and subsequent studies have replicated positive effects. However, the specific scents matter less than consistency and concentration. More recent research, including work by Pellegrino et al. (2021, JAMA Otolaryngology), suggests high-intensity odorants may outperform the classic Hummel set. One thing the video does not mention: persistent unilateral anosmia or anosmia with headache, visual changes, or other neurological symptoms warrants imaging, not just ENT follow-up. If your smell loss is one-sided and did not follow a clear illness, that is a red flag for something other than post-viral dysfunction. See a doctor before you start sniffing eucalyptus twice a day.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Movability · TikTok creator

16.4K views on this video

Lost your sense of smell after being sick? This is called post-viral olfactory dysfunction (anosmia). It’s common after colds, flu, and especially COVID. I pulled this from peer-reviewed studies, ENT

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about brann et al. (2020, chemical senses) confirmed sustentacular support cells,?

Brann et al. (2020, Chemical Senses) confirmed sustentacular support cells, not olfactory neurons directly, are the primary COVID-19 target in the olfactory epithelium, explaining smell loss without nasal congestion.

What does the video say about a 2022 laryngoscope systematic review found median smell recovery after?

A 2022 Laryngoscope systematic review found median smell recovery after COVID-19 at roughly 30 days, but a meaningful subset takes 3 or more months, and some cases persist beyond a year.

What does the video say about the 4-scent olfactory training protocol in this video matches the?

The 4-scent olfactory training protocol in this video matches the Hummel et al. (2009) RCT design, which is the most-cited evidence base for this intervention and has been replicated in post-COVID cohorts.

What does the video say about the fda?

The FDA issued a 2009 safety warning on intranasal zinc products after reports of permanent smell loss; the creator's warning to avoid zinc nasal sprays is clinically valid.

What does the video say about parosmia, where familiar smells?

Parosmia, where familiar smells are distorted or smell unpleasant, is a recognized phase of olfactory recovery and often signals active neural rewiring rather than worsening, according to long-COVID clinic data.

What does the video say about unilateral anosmia, smell loss with no preceding illness,?

Unilateral anosmia, smell loss with no preceding illness, or anosmia accompanied by headache or neurological symptoms requires imaging and specialist evaluation, not home smell training.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Movability, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.